Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

patient expectations

- PMLiVE

The dissemination and consumption of medical literature is evolving

QxMD, part of the WebMD Health Network discusses how they are going to evolve its publication solution, Read by QxMD in 2023.

Medscape Medical Affairs

- PMLiVE

World Antimicrobial Awareness Week 2022

Reports from the World Health Organization show that AMR is one of the top ten threats to global health, causing 1.3 million deaths in 2019

How to Increase Engagement During Virtual Events

Tip #7 - How do you increase engagement during virtual events? Make it fun! ️ See all Top 10 tips: https://www.impetusdigital.com/2021/03/25/top-10-tips-to-increase-engagement-during-virtual-events/

Impetus Digital

Biogen Idec building

Biogen and Alcyone Therapeutics partner in deal worth over $50m

The companies hope to improve treatments for spinal muscular atrophy and amyotrophic lateral sclerosis

- PMLiVE

Moderna to acquire OriCiro Genomics for $85m

The deal includes the Japanese DNA supplier’s synthetic biology and enzyme technologies

- PMLiVE

Tiziana’s foralumab shows continued clinical improvement in secondary progressive MS

MS affects around 700,000 people in Europe and approximately 2.5 million people worldwide

- PMLiVE

First UK proton beam therapy trial launches for certain breast cancer patients

The trial will assess the therapy in patients at risk of heart problems after standard radiotherapy

- PMLiVE

Design considerations and best practices in clinical research

The increased focus on precision medicine in oncology and rare diseases has led to a marked increase of single-arm trials

- PMLiVE

Gilead and EVOQ Therapeutics partner in deal potentially worth over $650m

The companies will focus on developing therapies for rheumatoid arthritis and lupus

- PMLiVE

Valneva reports additional data for COVID-19 booster

VLA2001 was well tolerated in participants previously vaccinated with an mRNA vaccine

- PMLiVE

Novavax initiates phase 2 combination COVID-19/flu vaccine study

Initial results from the trial are expected towards the middle of the year

- PMLiVE

RQ Bio-discovered antibody enters clinic as part of AstraZeneca COVID-19 study

The trial will evaluate the UK-based biotech’s AZD3152 in combination with cilgavimab

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links